According to a recent report by Market.us, the Global Acromegaly Treatment Market size is expected to be worth around USD 3.4 Billion by 2033 from USD 1.6 Billion in 2023, growing at a CAGR of 7.7% ...

Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal ...

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings ...

H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on CRNX stock, giving a Buy rating today. Douglas Tsao has given his ...

Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing's Syndrome Will be Presented at ENDO June ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report).

Hello, and welcome to the OPKO Health first-quarter 2024 financial results conference call. [Operator instructions] Please ...

Jeison Rodriguez Hernandez, a 28-year-old Venezuelan man with the world's largest feet, received custom-made shoes from a ...

The study of several families with Laron Syndrome in Ecuador opens up the possibility of searching for a drug or diet that ...

Global Peptide Therapeutics Industry is valued at US$ 38.0 Bn for 2023 & expected to reach US$ 106.0 Bn by 2033 at a CAGR of ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified ...